Otonomy
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
4796 Executive Dr, San Diego, California...Phone Number
(619) 323-2200Website
www.otonomy.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Otonomy
Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus.Explore more
Otonomy Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Otonomy your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Otonomy has new funding data
Check out if Otonomy is spiking on competitors!
Click to see if Otonomy had a recent Job posting/layoffs
Otonomy, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Otonomy
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Otonomy launches new products
Earning: See what the market has to say on Otonomy recently announced quarterly report
Check if Otonomy has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Otonomy as Masked Content
Find 3 more new buyers
Compare Similar Companies to Otonomy
Compare insights from companies similar to Otonomy, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Otonomy is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Otonomy is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Otonomy.
Otonomy financials insights
Gather financial insights about Otonomy, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Series A
$10M
Series B
$38.5M
2013
Series C
$45.9M
2014
Series D
$49M
Stock Offering
$104M
2015
Stock Offering
$86M
2016
Stock Offering
$115M
Otonomy Tech Stack
A closer look at the technologies used by Otonomy
See more technologies
Most Recent Scoops
Left Company
Executive Move
Mergers & Acquisitions (M&A)
Layoffs
Pain Point
Employee Relations, Facilities Management
Lateral Move
Executive Move
Left Company
Executive Move
Otonomy News & Media
Otonomy Provides Corporate Update
SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution (“Plan of Dissolution”) that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including the proceeds from the sale of any pipeline assets. To reduce cost, Otonomy has implemented a reduction in wOtonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Evaluation of strategic options to realize value from pipeline is ongoing Evaluation of strategic options to realize value from pipeline is ongoingOtonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss
SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the clinical evaluation of higher doses for OTO-413 (0.75 mg and 1.50 mg) in patients with hearing loss demonstrated no clinically meaningful improvement for patients from baseline across multiple speech-in-noise (SIN) hearing tests. These results are in contrast to the positive clinical signal observeOtonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus
SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the OTO-313 Phase 2 trial in tinnitus demonstrated no clinically meaningful benefit versus placebo for primary and secondary endpoints across all timepoints.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Otonomy
Sign Up For FreeTo access detailed company insights
Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is be... Read More
